The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 253.50
Bid: 250.50
Ask: 251.50
Change: 2.50 (1.00%)
Spread: 1.00 (0.399%)
Open: 246.50
High: 253.50
Low: 246.50
Prev. Close: 251.00
CSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on AGM Voting

15 Nov 2023 07:00

RNS Number : 4553T
Chesnara PLC
15 November 2023
 

 

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

15th November 2023

 

CHESNARA plc

("Chesnara", the "Company" or the "Group")

 

RESPONSE TO VOTING RESULTS AT 2023 ANNUAL GENERAL MEETING

 

In accordance with Provision-4 of the UK Corporate Governance Code, Chesnara (CSN.L), the European life insurance consolidator, today provides an update to our statement of 16th May 2023 regarding the result of the poll vote at the 2023 Annual General Meeting ("AGM") on Resolution-2 to approve the Directors' Remuneration Report.

 

Resolution-2 passed with 72.66% of votes in favour. Since the AGM, the Remuneration Committee has engaged with the Company's major shareholders and proxy agencies to help understand the reasons for votes cast against Resolution-2. Three areas have been identified, which are in line with those raised by proxy investor bodies in their respective reports published just in advance of the 2023 AGM. We set them out below, alongside the proposed response to each.

 

 

LTIP to be Based One Third on Surplus Emergence

 

One area of feedback related to the use of cash generation metrics in both the Short Term Incentive Scheme ("STIS") and Long Term Incentive Plan ("LTIP"). In response to this, for LTIP awards granted in FY24, the Commercial Cash Generation metric will be replaced by a new Surplus Emergence metric. The existing relative TSR and Economic Value growth metrics will be retained. Each metric will be weighted one third of the assessment in line with the current approach.

 

Surplus Emergence will be one of the Group's KPIs and will be consistent with the definition used for reporting elsewhere in the annual report and the Company's other trading updates. It represents the operational surplus that has been generated in the period, largely a function of the movement in the solvency position of the insurance subsidiaries within the Group and takes account of the buffers that management has set to hold over and above the solvency requirements imposed locally by our regulators.

 

 

All LTIP Performance Targets to be Disclosed Prospectively

 

Shareholders expressed a preference for LTIP performance targets to be disclosed prospectively, in line with the approach the Company has always taken for the relative TSR metric. The Company acknowledges that this is increasingly common practice and going forward will disclose threshold targets prospectively going forwards, commencing with the targets for the LTIP awards to be granted in 2024.

 

 

Assessment of the Company's M&A Activity Within the Strategic Scorecard of the STIS

 

For 2024, the Remuneration Committee is proposing to make a small modification to the performance measures to be included in the STIS. The Strategic Scorecard (30% weighting) will be replaced by an ESG metric (5% weighting) and a Strategic Activity Scorecard (25% weighting) which focuses on the assessment of value-enhancing strategic activities including M&A, management actions, operational programme delivery and pipeline development. The weightings within the Strategic Activity Scorecard will vary year-to-year to reflect the relative priorities for the Company.

 

This means the assessment of M&A activity for the FY24 STIS will be entirely contained within the Strategic Activity Scorecard with no discretion applied. Full details of the assessment of the Strategic Activity Scorecard will be included in the Directors' Remuneration Report each year.

 

 

 

 

 

The Remuneration Committee would like to thank the major shareholders who have engaged in the consultation exercise since the AGM and believes that the proposed changes address the key issues raised. In accordance with the Corporate Governance Code, a final summary will be provided in the Company's 2023 Annual Report.

 

 

 

For further information, please contact:

 

Investor Enquiries

Sam Perowne

Head of Strategic Development & Investor Relations

Chesnara plc

E - sam.perowne@chesnara.co.uk

 

Media Enquiries

Roddy Watt

Director, Capital Markets

FWD

T - 020 7280 0651 / 07714 770 493 

E - roddy.watt@fwdconsulting.co.uk

 

 

Notes to Editors

Chesnara (CSN.L) is a European life and pensions consolidator listed on the London Stock Exchange. It administers approximately one million policies and operates as Countrywide Assured and CASLP in the UK, as The Waard Group and Scildon in the Netherlands and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 18 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMNKQBDFBDDODD
Date   Source Headline
10th Aug 201612:17 pmRNSNotice of Results
4th Jul 201610:32 amRNSHolding(s) in Company
14th Jun 20164:30 pmRNSNotification of director share interest
25th May 20161:41 pmRNSHolding(s) in Company
19th May 20167:00 amRNSDirectorate Change
19th May 20167:00 amRNSAppointment of new joint broker
19th May 20167:00 amRNSResult of AGM
28th Apr 20162:32 pmRNSDirector/PDMR Shareholding
20th Apr 20167:00 amRNSAnnual Financial Report 2015 and AGM Notice
31st Mar 20167:00 amRNSFinal Results
24th Mar 20168:45 amRNSNotice of Results
11th Mar 20163:45 pmRNSHolding(s) in Company
3rd Mar 20168:34 amRNSStatement re Legacy Review
30th Nov 20151:56 pmRNSHolding(s) in Company
19th Nov 20157:00 amRNSInterim Management Statement
13th Oct 20156:17 pmRNSHolding(s) in Company
28th Aug 20157:00 amRNSHalf Yearly Report
10th Aug 201511:22 amRNSNotice of Results
20th May 20157:00 amRNSAcquisition
15th May 201511:56 amRNSResult of AGM
11th May 20154:17 pmRNSRegulatory Approval
28th Apr 20153:40 pmRNSDirector/PDMR Shareholding
27th Apr 20159:51 amRNSAnnual Financial Report
15th Apr 20157:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Mar 20157:00 amRNSFinal Results
9th Mar 20158:48 amRNSNotice of Results
25th Feb 20159:29 amRNSHolding(s) in Company
21st Jan 20154:01 pmRNSDirector/PDMR Shareholding
5th Dec 20147:00 amRNSRegulatory Approval
4th Dec 201412:30 pmRNSPart VII Transfer Approval
3rd Dec 201412:58 pmRNSResults of Placing
3rd Dec 20147:01 amRNSProposed Acquisition and Placing
3rd Dec 20147:00 amRNSDirectorate Change
19th Nov 20147:00 amRNSInterim Management Statement
7th Nov 201412:54 pmRNSTotal Voting Rights
4th Nov 201410:18 amRNSDirector/PDMR Shareholdings / Total Voting Rights
9th Sep 20142:39 pmRNSHolding(s) in Company
29th Aug 20147:00 amRNSHalf Yearly Report
11th Aug 20144:01 pmRNSNotice of Results
21st Jul 201411:42 amRNSTotal Voting Rights
7th Jul 20141:41 pmRNSContract with HCL
19th Jun 20142:06 pmRNSDirectorate Change
20th May 20142:43 pmRNSDirector/PDMR Shareholding
19th May 20147:00 amRNS1st Quarter Results
16th May 201411:40 amRNSResult of AGM
28th Apr 201411:42 amRNSAnnual Financial Report
14th Apr 201412:26 pmRNSAnnual Report and Accounts and Notice of AGM
28th Mar 20141:28 pmRNSDirector/PDMR Shareholding
28th Mar 20147:01 amRNSFinal Results
10th Mar 201412:00 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.